These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37990197)

  • 1. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.
    Swart KMA; Baak BN; Lemmens L; Penning-van Beest FJA; Bengtsson C; Lobier M; Hoti F; Vojinovic D; van Burk L; Rhodes K; Garbe E; Herings RMC; Nordon C; Simons SO
    Respir Res; 2023 Nov; 24(1):293. PubMed ID: 37990197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan.
    Matsunaga K; Yoshida Y; Makita N; Nishida K; Rhodes K; Nordon C
    Adv Ther; 2024 Aug; 41(8):3362-3377. PubMed ID: 38976123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany.
    Vogelmeier CF; Rhodes K; Garbe E; Abram M; Halbach M; Müllerová H; Kossack N; Timpel P; Kolb N; Nordon C
    BMJ Open Respir Res; 2024 Mar; 11(1):. PubMed ID: 38555102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease-A Nationwide, Population-Based Cohort Study.
    Løkke A; Hilberg O; Lange P; Ibsen R; Telg G; Stratelis G; Lykkegaard J
    Int J Chron Obstruct Pulmon Dis; 2023; 18():419-429. PubMed ID: 37034899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies.
    Nordon C; Rhodes K; Quint JK; Vogelmeier CF; Simons SO; Hawkins NM; Marshall J; Ouwens M; Garbe E; Müllerová H
    BMJ Open; 2023 Apr; 13(4):e070022. PubMed ID: 37185641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease.
    Hawkins NM; Nordon C; Rhodes K; Talukdar M; McMullen S; Ekwaru P; Pham T; Randhawa AK; Sin DD
    Heart; 2024 Apr; 110(10):702-709. PubMed ID: 38182279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study.
    Daniels K; Lanes S; Tave A; Pollack MF; Mannino DM; Criner G; Neikirk A; Rhodes K; Feigler N; Nordon C
    Int J Chron Obstruct Pulmon Dis; 2024; 19():225-241. PubMed ID: 38259591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain.
    Santos S; Manito N; Sánchez-Covisa J; Hernández I; Corregidor C; Escudero L; Rhodes K; Nordon C
    Rev Esp Cardiol (Engl Ed); 2024 Jun; ():. PubMed ID: 38936468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study.
    Graul EL; Nordon C; Rhodes K; Marshall J; Menon S; Kallis C; Ioannides AE; Whittaker HR; Peters NS; Quint JK
    Am J Respir Crit Care Med; 2024 Apr; 209(8):960-972. PubMed ID: 38127850
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis.
    Müllerová H; Marshall J; de Nigris E; Varghese P; Pooley N; Embleton N; Nordon C; Marjenberg Z
    Ther Adv Respir Dis; 2022; 16():17534666221113647. PubMed ID: 35894441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial.
    Dransfield MT; Criner GJ; Halpin DMG; Han MK; Hartley B; Kalhan R; Lange P; Lipson DA; Martinez FJ; Midwinter D; Singh D; Wise R; Kunisaki KM
    J Am Heart Assoc; 2022 Sep; 11(18):e024350. PubMed ID: 36102236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
    Fraser A; Poole P
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study.
    Santus P; Di Marco F; Braido F; Contoli M; Corsico AG; Micheletto C; Pelaia G; Radovanovic D; Rogliani P; Saderi L; Scichilone N; Tanzi S; Vella M; Boarino S; Sotgiu G; Solidoro P
    Int J Chron Obstruct Pulmon Dis; 2024; 19():607-618. PubMed ID: 38444551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events after exacerbations of chronic obstructive pulmonary disease: Results from the EXAcerbations of COPD and their OutcomeS in CardioVascular diseases study in Italy.
    Calabria S; Ronconi G; Dondi L; Dondi L; Dell'Anno I; Nordon C; Rhodes K; Rogliani P; Dentali F; Martini N; Maggioni AP
    Eur J Intern Med; 2024 Sep; 127():97-104. PubMed ID: 38729787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study.
    Yang HM; Ryu MH; Carey VJ; Kinney GL; Hokanson JE; Dransfield MT; Hersh CP; Silverman EK;
    J Am Heart Assoc; 2024 Jun; 13(11):e033882. PubMed ID: 38818936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
    Yang T; Cai B; Cao B; Kang J; Wen F; Chen Y; Jian W; Wang C
    Ther Adv Respir Dis; 2023; 17():17534666231167353. PubMed ID: 37073797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.
    Løkke A; Hilberg O; Lange P; Ibsen R; Stratelis G; de Fine Licht S; Lykkegaard J
    Int J Chron Obstruct Pulmon Dis; 2022; 17():569-578. PubMed ID: 35321533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial.
    Wells JM; Criner GJ; Halpin DMG; Han MK; Jain R; Lange P; Lipson DA; Martinez FJ; Midwinter D; Singh D; Wise RA
    Chronic Obstr Pulm Dis; 2023 Jan; 10(1):33-45. PubMed ID: 36516330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD.
    Fawzy A; Anderson JA; Cowans NJ; Crim C; Wise R; Yates JC; Hansel NN
    Respir Res; 2019 May; 20(1):86. PubMed ID: 31068182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.